NCT03061981已完成1 期
A Phase I, First In Human, Double Blind, Placebo Controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Interaction Effect With Metformin Following A Single Oral Dose Of DA-1241 In Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- [Safety and Tolerability] 12-lead ECGs, Vital signs. Physical examinations, Clinical laboratory testing and Adverse event assessments
研究概览
简要总结
This is a randomized, double blind, placebo controlled, single ascending dose study to assess the safety, tolerability, PK, PD and IE with metformin following a single oral dose of DA-1241 in healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Double Blind
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent before any of the screening procedures are performed.
- •Male subjects aged between 18 and 55 years (both inclusive) at screening.
- •Body mass index (BMI) of 18.5 to 32.0 kg/m2 (both inclusive) at screening.
- •Medical history, vital signs, physical examination, standard 12-lead ECGs and laboratory investigations (clinical chemistry, hematology and urinalysis) must be clinically acceptable or within laboratory reference ranges for the relevant laboratory tests, unless the PI considers the deviation to be irrelevant for the purpose of the study. These assessments may be repeated once at the discretion of the PI.
- •Subjects with partners of childbearing potential must be willing to use medically acceptable double barrier forms of contraception from IMP administration until at least 3 months after the last day of IMP administration. Subjects must not donate sperm for the duration of the study and for at least 3 months after the last day of IMP administration.
- •Is a non-smoker or non-tobacco/nicotine user confirmed with urine cotinine test at screening and on admission to the EPCU. Nicotine products include, but are not limited to, tobacco cigarettes, electronic cigarettes, snuff, cigars, and pipes, including hookah or water pipes. The use of nicotine patches or gum (e.g., products used as part of a smoking cessation program) is not allowed.
排除标准
- •Has a known hypersensitivity to any component of the formulation of DA- 1241 or any of the excipients or to medicinal products with similar chemical structures.
- •Has a history or presence of any clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal or endocrine disease or other abnormality that may impact the ability of the subject to participate or potentially confound the study results.
- •Has a glycated hemoglobin A1C (HgbA1C) of ≥ 6.5% consistent with possible diabetes at screening.
- •Any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs.
- •Any concurrent disease or condition that, in the opinion of the PI, would make the subject unsuitable for participation in the clinical study.
- •Subject has a history of drinking > 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the EPCU.
- •Have positive test results for Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibodies (anti HCV) or human immunodeficiency virus 1 and/or -2 antibodies (anti HIV-1 and/or -2) at screening.
- •History of drug abuse or has a positive urine drug test (cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids, etc.) at screening or on Day
- •Has donated or lost 450 mL or more of his blood volume (including plasmaphoresis), or had a transfusion of any blood product within 3 months before screening.
- •Taking any medication including prescription, herbal remedies, vitamin supplements, dietary supplements or other over-the-counter (OTC) products within 14 days or 5 half-lives of the product (whichever period is longer) before admission to the EPCU.
- •Has an abnormal (clinically significant) ECG at screening or on Day
- •Entry of any subject with an abnormal (but not clinically significant) ECG must be approved and documented by signature, by the PI or medically qualified Sub-investigator.
- •Has a supine blood pressure (BP) outside the ranges of 90 to 140 mmHg, inclusive, for systolic BP and 50 to 90 mmHg, inclusive, for diastolic BP, or has a resting heart rate outside the range of 45 to 100 beats per minute (bpm). If any of the values are out of range, the assessment may be repeated once for eligibility determination, at screening and admission on Day
- •Has a corrected QT interval using Fridericia's corrected formula (QTcF) interval greater than 450 msec or PR interval outside the range of 120 to 220 msec. If any values are out of range, the ECG may be repeated once for eligibility determination, at screening and admission on Day
- •Has an abnormal laboratory value that suggests a clinically significant underlying disease or has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values greater than 1.5 times the upper limit of normal (ULN). Laboratory assessments may be repeated once to confirm eligibility at screening and on Day
- •Participation in another study with an experimental drug within 30 days or 5 half-lives, whichever is longer, of this study's screening visit. Participation is defined as the date of last dose received in the previous study.
- •Unwilling to abstain from vigorous exercise within 48 hours before Day
- •Intake of any food or drinks containing grapefruit, Chinese grapefruit (pomelo), star fruit, pomegranate or Seville orange (including marmalade) within 48 hours before admission to the EPCU.
- •Have used alcohol within 72 hours prior to screening or within 72 hours prior to admission to the EPCU.
- •Is unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study.
- •Is a study-site employee or an immediate family member or dependent (e.g., spouse, parent, child or sibling) of a study-site employee who is involved in the conduct of this study.
- •Has difficulty swallowing 2 tablets at the same time.
研究组 & 干预措施
DA-1241:8 subjects in each cohort(Cohort 1-6)
Active Comparator
Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
干预措施: DA-1241 (Drug)
Placebo: 2 subjects in each cohort(Cohort 1-6)
Placebo Comparator
Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
干预措施: Placebo (Drug)
DA-1241 in IE Cohort: 8 subjects in choosen cohort
Other
One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
干预措施: Metformin (Drug)
DA-1241 in IE Cohort: 8 subjects in choosen cohort
Other
One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
干预措施: DA-1241 (Drug)
Placebo in IE Cohort: 2 subjects in choosen cohort
Other
One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
干预措施: Placebo (Drug)
Placebo in IE Cohort: 2 subjects in choosen cohort
Other
One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
干预措施: Metformin (Drug)
结局指标
主要结局
[Safety and Tolerability] 12-lead ECGs, Vital signs. Physical examinations, Clinical laboratory testing and Adverse event assessments
时间窗: Through study completion, an average of 40 days for each treatment period
次要结局
- Maximum concentration of DA-1241 (Cmax)(Through the treatment period; 72 hours)
- Time of maximum plasma DA-1241 concentration (Tmax)(Through the treatment period; 72 hours)
- Area under the concentration-time curve (AUC)(Through the treatment period; 72 hours)
- Apparent terminal elimination half-life (t½)(Through the treatment period; 72 hours)
- Apparent total systemic clearance after oral administration (CL/F)(Through the treatment period; 72 hours)
- Apparent volume of distribution (Vz/F)(Through the treatment period; 72 hours)
- Amount of DA-1241 excreted unchanged in the urine in each collection interval(Ae)(Through the treatment period; 72 hours)
- Cumulative amount of DA-1241 excreted unchanged in the urine (Cum Ae)(Through the treatment period; 72 hours)
- Percentage fraction of DA-1241 excreted unchanged in the urine in each collection interval(Fe)(Through the treatment period; 72 hours)
- Cumulative percentage fraction of DA-1241 excreted unchanged in the urine (Cum Fe)(Through the treatment period; 72 hours)
- Renal clearance (CLR)(Through the treatment period; 72 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy VolunteersHealthy VolunteerNCT01597947Achaogen, Inc.50
Unknown
1 期
A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APBContact DermatitisNCT04853823Hapten Sciences, Inc.32
已完成
1 期
A Phase I, Single-Center Study of PDC-APB in Healthy VolunteersContact DermatitisNCT02700373Hapten Sciences, Inc.40
已完成
1 期
A Single Dose Study of SHR0410 in Healthy Male ParticipantsAcute PainNCT03493191Atridia Pty Ltd.48
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)Cardiovascular DiseaseNCT03626662Amgen79